Contribution of endogenous glucocorticoids and their intravascular metabolism by 11β-HSDs to postangioplasty neointimal proliferation in mice

Endocrinology

Volumn 153, Issue 12, 2012, Pages 5896-5905

  Iqbal, Javaid ^a   Macdonald, Linsay J ^a   Low, Lucinda ^a   Seckl, Jonathan R ^a   Yau, Christopher W ^a   Walker, Brian R ^a   Hadoke, Patrick W F ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; APOLIPOPROTEIN E; DEXAMETHASONE; EPLERENONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MIFEPRISTONE;

ADRENALECTOMY; ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMORAL ARTERY; MACROPHAGE; MALE; METABOLISM; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADRENALECTOMY; ANGIOPLASTY; ANIMALS; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMORAL ARTERY; GLUCOCORTICOIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIFEPRISTONE; NEOINTIMA; POSTOPERATIVE PERIOD; REGENERATION; RISK;

EID: 84870197180     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1481     Document Type: Article

References (36)

1. Hadoke PW, Iqbal J, Walker BR 2009 Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 156:689-712
2. Walker BR 2007 Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545-559
3. Hughes KA, Webster SP, Walker BR 2008 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in type 2 diabetes mellitus and obesity 3390. Expert Opin Investig Drugs 17:481-496
4. Seckl JR, Walker BR 2001 11β-Hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376
5. Stewart PM, Krozowski ZS 1999 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57:249-324
6. Walker BR, Yau JL, Brett LP, Seckl JR, Monder C, Williams BC, Edwards CR 1991 11β-Hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 129:3305-3312
7. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR 2003 Glucocorticoid action in mouse aorta; localisation of 11β-hydroxysteroid dehydrogenase type 2 and effects on response to glucocorticoid in vitro. Hypertension 42:580-587
8. Van Belle E, Bauters C, Wernert N, Hamon M, McFadden EP, Racadot A, Dupuis B, Lablanche JM, Bertrand ME 1995 Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist. Cardiovasc Res 29:27-32
9. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472
10. Wakabayashi K, Suzuki H, Sato T, Iso Y, Katagiri T, Takeyama Y 2006 Eplerenone suppresses neointimal formation after coronary stent implantation in swine. Int J Cardiol 107:260-266
11. Hadoke PW, Christy C, Kotelevtsev YV, Williams BC, Kenyon CJ, Seckl JR, Mullins JJ, Walker BR 2001 Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11β-hydroxysteroid dehydrogenase. Circulation 104:2832-2837
12. Small GR, Hadoke PW, Sharif I, Dover AR, Armour D, Kenyon CJ, Gray GA, Walker BR 2005 Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA 102:12165-12170
13. Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, Harris HJ, Mullins JJ, Seckl JR, Savill JS, Chapman KE 2006 Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176:7605-7611
14. Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE 2012 11β-Hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 153:234-240
15. Libby P 2002 Inflammation in atherosclerosis. Nature 420:868-874
16. Poon M, Gertz SD, Fallon JT, Wiegman P, Berman JW, Sarembock IJ, Taubman MB 2001 Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol-fed rabbits. Atherosclerosis 155:371-380
17. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R 2005 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527
18. Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM 2009 Antidiabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 11:688-699
19. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ 1999 Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J Clin Invest 103:683-689
20. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ 1997 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929
21. Dover AR, Hadoke PW, Macdonald LJ, Miller E, Newby DE, Walker BR 2007 Intravascular glucocorticoid metabolism during inflammation and injury in mice. Endocrinology 148:166-172
22. Al-Dujaili EA, Forrest GC, Edwards CR 1979 Development and application of an automated direct radioimmunoassay for plasma aldosterone [proceedings]. J Endocrinol 81:111P
23. Soro A, Panarelli M, Holloway CD, Fraser R, Kenyon CJ 1997 In vivo and in vitro effects of carbenoxolone on glucocorticoid receptor binding and glucocorticoid activity. Steroids 62:388-394
24. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M 2006 Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26:917-921
25. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
26. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
27. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ 2004 Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088-7093
28. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938
29. Deuchar GA, McLean D, Hadoke PW, Brownstein DG, Webb DJ, Mullins JJ, Chapman K, Seckl JR, Kotelevtsev YV 2011 11β-Hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apo-E-/- mice. Endocrinology 152:236-246
30. Iwanami J, Mogi M, Okamoto S, Gao XY, Li JM, Min LJ, Ide A, Tsukuda K, Iwai M, Horiuchi M 2007 Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model. Eur J Pharmacol 566:153-159
31. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M 2003 Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 41:955-963
32. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R 2010 The 11β- Hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516-1522
33. Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD 2011 Effects of an 11β- hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13:498-504
34. Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB, Feig PU 2011 Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens 5:166-176
35. Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A 2001 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 167:30-35
36. Wamil M, Battle JH, Turban S, Kipari T, Seguret D, de Sousa Peixoto R, Nelson YB, Nowakowska D, Ferenbach D, Ramage L, Chapman KE, Hughes J, Dunbar DR, Seckl JR, Morton NM 2011 Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 60:1158-1167